Clinical Trials

29 Apr 2019
- Clinical Trials
- Human Trials
Navidea announces comparative study to evaluate tilmanocept in patients with TB

By PBR Staff Writer

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Professor Mike Sathekge, MBChB, M. Med (Nuclear Medicine), PhD Professor and Head of the Department of Nuclear Medicine in the Faculty of Health Sciences at the University of Pretoria/Steve Biko Academic Hospital, plans to initiate a comparative study evaluating the use of Tilmanocept in patients with TB.
26 Apr 2019
Clinical Trials
Human Trials
Merck’s Keytruda yields mixed results in phase 3 KEYNOTE-062 trial

By PBR Staff Writer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
26 Apr 2019
Clinical Trials
Human Trials
Gilead’s selonsertib fails to meet primary endpoint in Phase 3 NASH study

By PBR Staff Writer

Gilead Sciences’ selonsertib has failed to achieve primary end point in the Phase 3 study of nonalcoholic steatohepatitis (NASH).
25 Apr 2019
Clinical Trials
Human Trials
Teva to discontinue ENFORCE program for fremanezumab due to futility

By PBR Staff Writer

Teva Pharmaceutical Industries said that it will stop an ongoing clinical development program of its humanized monoclonal antibody fremanezumab in cluster headaches due to futility.
24 Apr 2019
Clinical Trials
Human Trials
Lilly’s Taltz meets primary endpoint in phase 3 nr-axSpA trial

By PBR Staff Writer

Eli Lilly and Company (Lilly) has announced that its psoriatic arthritis drug Taltz (ixekizumab) succeeded in a phase 3 trial in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
23 Apr 2019
Clinical Trials
Human Trials
Forbius announces first patient dosed in phase 2a EGFR-overexpressing TNBC trial of AVID100

By PBR Staff Writer

Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC).
22 Apr 2019
Clinical Trials
Human Trials
Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial

By PBR Staff Writer

Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
16 Apr 2019
Clinical Trials
Human Trials
Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1

By PBR Staff Writer

Alnylam Pharmaceuticals has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1).
15 Apr 2019
Clinical Trials
Human Trials
Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH

By PBR Staff Writer

Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).
12 Apr 2019
Clinical Trials
Human Trials
Janssen’s HIV drug SYMTUZA yields positive results in DIAMOND trial

By PBR Staff Writer

Janssen Pharmaceutical said that a phase 3 trial evaluating SYMTUZA (darunavir 800mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide 10mg D/C/F/TAF) showed that a high percentage of HIV patients recorded an undetectable viral load through 48 weeks after rapid initiation of the drug.

Drug Discovery

Research & Development

Superluminal Medicines secures $60m to advance rare obesity therapy

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG

Gerresheimer at CPHI Frankfurt 2025

Suppliers

No data found

Clinical Trials

Navidea announces comparative study to evaluate tilmanocept in patients with TB

Merck’s Keytruda yields mixed results in phase 3 KEYNOTE-062 trial

Gilead’s selonsertib fails to meet primary endpoint in Phase 3 NASH study

Teva to discontinue ENFORCE program for fremanezumab due to futility

Lilly’s Taltz meets primary endpoint in phase 3 nr-axSpA trial

Forbius announces first patient dosed in phase 2a EGFR-overexpressing TNBC trial of AVID100

Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial

Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1

Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH

Janssen’s HIV drug SYMTUZA yields positive results in DIAMOND trial

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found